Hao YP. Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent Mycoplasma pneumoniae and Epstein-Barr virus infections. World J Clin Cases 2024; 12(23): 5346-5353 [PMID: 39156096 DOI: 10.12998/wjcc.v12.i23.5346]
Corresponding Author of This Article
Yan-Ping Hao, MBBS, Doctor, Department of Pediatrics, Maternal and Child Health Hospital, No. 261 Shanhu Road, Shengzhou, Shaoxing 312400, Zhejiang Province, China. yanpingh0021@163.com
Research Domain of This Article
Pediatrics
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 5 Logistic regression analysis of factors affecting poor prognosis in children with Epstein-Barr virus coinfection in Mycoplasma pneumoniae pneumonia
Variate
β
SE
Wald χ2
P value
OR
95%CI
IL-2
1.186
0.496
5.847
0.013
3.865
1.235-7.475
IL-12
1.074
0.426
6.194
0.012
0.384
0.156-0.836
CRP
0.516
0.319
2.496
0.136
1.858
0.843-3.285
Fever
0.173
0.264
0.395
0.586
1.124
0.656-2.184
Citation: Hao YP. Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent Mycoplasma pneumoniae and Epstein-Barr virus infections. World J Clin Cases 2024; 12(23): 5346-5353